β-Adrenergic receptor subtype signaling in heart: From bench to bedside
Abstract
β-adrenergic receptor (βAR) stimulation by the sympathetic nervous system or circulating catecholamines is broadly involved in peripheral blood circulation, metabolic regulation, muscle contraction, and central neural activities. In the heart, acute βAR stimulation serves as the most powerful means to regulate cardiac output in response to a fight-or-flight situation, whereas chronic βAR stimulation plays an important role in physiological and pathological cardiac remodeling.
There are three βAR subtypes, β1AR, β2AR and β3AR, in cardiac myocytes. Over the past two decades, we systematically investigated the molecular and cellular mechanisms underlying the different even opposite functional roles of β1AR and β2AR subtypes in regulating cardiac structure and function, with keen interest in the development of novel therapies based on our discoveries. We have made three major discoveries, including (1) dual coupling of β2AR to Gs and Gi proteins in cardiomyocytes, (2) cardioprotection by β2AR signaling in improving cardiac function and myocyte viability, and (3) PKA-independent, CaMKII-mediated β1AR apoptotic and maladaptive remodeling signaling in the heart. Based on these discoveries and salutary effects of β1AR blockade on patients with heart failure, we envision that activation of β2AR in combination with clinically used β1AR blockade should provide a safer and more effective therapy for the treatment of heart failure.
Keywords:
There are three βAR subtypes, β1AR, β2AR and β3AR, in cardiac myocytes. Over the past two decades, we systematically investigated the molecular and cellular mechanisms underlying the different even opposite functional roles of β1AR and β2AR subtypes in regulating cardiac structure and function, with keen interest in the development of novel therapies based on our discoveries. We have made three major discoveries, including (1) dual coupling of β2AR to Gs and Gi proteins in cardiomyocytes, (2) cardioprotection by β2AR signaling in improving cardiac function and myocyte viability, and (3) PKA-independent, CaMKII-mediated β1AR apoptotic and maladaptive remodeling signaling in the heart. Based on these discoveries and salutary effects of β1AR blockade on patients with heart failure, we envision that activation of β2AR in combination with clinically used β1AR blockade should provide a safer and more effective therapy for the treatment of heart failure.